Last updated: October 2026
The statistics, study design and research ethics that appear in every ophthalmology exam and every journal club, explained with eye examples. Includes a calculator for diagnostic test accuracy.
Diagnostic tests: the 2 × 2 table
| Disease present | Disease absent |
|---|
| Test positive | True positive (TP) | False positive (FP) |
| Test negative | False negative (FN) | True negative (TN) |
- Sensitivity = TP ÷ (TP + FN): of those with disease, how many test positive. A sensitive test, if negative, rules disease out (SnNout).
- Specificity = TN ÷ (TN + FP): of those without disease, how many test negative. A specific test, if positive, rules disease in (SpPin).
- Positive predictive value = TP ÷ (TP + FP) and negative predictive value = TN ÷ (TN + FN). These depend on prevalence: screening for glaucoma in the general population (low prevalence) gives many false positives even with a good test.
- Likelihood ratios: LR+ = sensitivity ÷ (1 − specificity); LR− = (1 − sensitivity) ÷ specificity. Unlike predictive values, they do not change with prevalence.
The default numbers show a test with 90% sensitivity and 90% specificity used where prevalence is 2%: the positive predictive value is only about 16%.
Measures of effect
| Measure | Formula | Example (event in 20% of controls, 15% of treated) |
|---|
| Absolute risk reduction (ARR) | Control risk − treated risk | 20% − 15% = 5% |
| Relative risk (RR) | Treated risk ÷ control risk | 0.15 ÷ 0.20 = 0.75 |
| Relative risk reduction (RRR) | 1 − RR | 25% |
| Number needed to treat (NNT) | 1 ÷ ARR | 1 ÷ 0.05 = 20 |
| Odds ratio (OR) | (a × d) ÷ (b × c) from a 2 × 2 table | Used in case–control studies; close to RR when the outcome is rare |
- Confidence interval: the range of values compatible with the data. If a 95% CI for an RR or OR includes 1 (or for a difference includes 0), the result is not statistically significant at p < 0.05.
- p-value: the probability of a result at least this extreme if there were truly no difference. It does not measure the size or importance of an effect.
- Type I error (α): finding a difference that is not real (false positive). Type II error (β): missing a real difference. Power = 1 − β, usually set at 80–90%; it rises with sample size and effect size.
Study designs and the evidence pyramid
| Design | What it does | Eye example | Main weakness |
|---|
| Systematic review and meta-analysis | Combines all good trials | Cochrane review of anti-VEGF for DME | Only as good as the included trials; publication bias (funnel plot asymmetry) |
| Randomised controlled trial | Random allocation removes confounding | LiGHT (SLT vs drops), Protocol T | Cost, strict selection limits generalisability |
| Cohort study | Follows exposed and unexposed people forward | Smokers vs non-smokers for cataract | Confounding, loss to follow-up |
| Case–control study | Compares cases with controls, looking back at exposures | Uveal melanoma and sunlight | Recall and selection bias |
| Cross-sectional study | Measures prevalence at one time point | Prevalence of glaucoma in a district | Cannot show cause and effect |
| Case series and case reports | Describe new findings | First reports of a drug side effect | No comparison group |
Common biases
- Selection bias: the study population does not represent the target population (for example, tertiary hospital patients used to estimate community prevalence).
- Lead-time bias: earlier diagnosis by screening makes survival look longer even if outcome is unchanged. Length-time bias: screening picks up slower, milder disease.
- Recall bias (case–control studies), observer bias (reduced by masking), attrition bias (dropouts), and publication bias.
- Confounding: a third factor linked to both exposure and outcome (for example, age in studies of diabetes and cataract). Randomisation, matching and multivariable analysis reduce it.
Trials: key terms
- Intention-to-treat: analyse people in the groups they were randomised to, whatever happened; preserves randomisation. Per-protocol: only those who completed treatment as planned.
- Masking (blinding): single (patient), double (patient and assessor). Non-inferiority trials test whether a new treatment is not worse than the standard by more than a set margin (for example faricimab vs aflibercept).
- Survival analysis: Kaplan–Meier curves for time-to-event data such as graft survival or trabeculectomy failure, compared with the log-rank test; hazard ratios from Cox regression.
Agreement and reliability
- Bland–Altman plot: agreement between two measurement methods (for example two tonometers): plots the difference against the mean, with the mean bias and 95% limits of agreement. Correlation is not agreement.
- Kappa statistic: agreement between observers beyond chance for categories (for example grading of diabetic retinopathy): above 0.8 is very good, 0.6–0.8 good.
- Intraclass correlation: reliability of continuous measurements.
Research ethics and consent
- The Declaration of Helsinki sets the principles for research involving people; studies need ethics committee approval and informed consent. In India, research follows the ICMR National Ethical Guidelines and trials are registered with CTRI.
- Consent for treatment: patients must be told about material risks, benefits and reasonable alternatives (UK: Montgomery 2015). Record the discussion, not just a signature.
- Confidentiality can be broken only in limited situations, such as serious risk to others (for example an unsafe driver who refuses to stop).
Related: landmark trials, thesis topics, how to write a case report.
Key sources
- Kirkwood BR, Sterne JAC. Essential Medical Statistics, 2nd ed. Blackwell; 2003
- Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307–10
- Indian Council of Medical Research. National Ethical Guidelines for Biomedical and Health Research Involving Human Participants, 2017
- World Medical Association. Declaration of Helsinki (2024 revision)